The promoter was used to drive ubiquitous expression of a human cDNA containing a 3 bp deletion (delta GAG) identified in patients with DYT1 dystonia. Two lines were created (hMT1 and hMT2) with a 2-fold and 1.2-fold increase in expression levels, respectively.